Cargando…

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report

BACKGROUND: Pregnancy is an unquantifiable risk to accelerate tumor growth of papillary thyroid carcinoma (PTC), and whether pregnancy induces an unfavorable prognosis of radioiodine refractory papillary thyroid carcinoma (RR-PTC) remains unknown. CASE PRESENTATION: We investigated the impact of pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Yuchen, Liu, Min, Cheng, Lingxiao, Chen, Libo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679339/ https://www.ncbi.nlm.nih.gov/pubmed/29121867 http://dx.doi.org/10.1186/s12885-017-3717-3

Ejemplares similares

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
por: Qiu, Xian, et al.
Publicado: (2022)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma
por: Li, Genpeng, et al.
Publicado: (2022)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
por: Wong, Kai-Pun, et al.
Publicado: (2012)

Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study
por: Liu, Hanqing, et al.
Publicado: (2023)

Targeting IGF2BP2 Promotes Differentiation of Radioiodine Refractory Papillary Thyroid Cancer via Destabilizing RUNX2 mRNA
por: Sa, Ri, et al.
Publicado: (2022)

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study
por: Fu, Hao, et al.
Publicado: (2019)

Synergic radiosensitization of sinomenine hydrochloride and radioiodine on human papillary thyroid carcinoma cells
por: Zhao, Aomei, et al.
Publicado: (2021)

The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF(V600E) Mutation
por: Anekpuritanang, Tauangtham, et al.
Publicado: (2021)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Salvage surgery for cervical radioiodine refractory (18)F-FDG-PET positive recurrence of papillary thyroid cancer
por: Chiapponi, C, et al.
Publicado: (2021)

Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?
por: Krčálová, Eva, et al.
Publicado: (2016)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
por: Alsaud, Arwa, et al.
Publicado: (2020)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
por: Sa, Ri, et al.
Publicado: (2020)

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
por: Qiu, Xian, et al.
Publicado: (2022)

Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma
por: Cadena-Piñeros, Enrique, et al.
Publicado: (2022)

Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy
por: Mishra, Ayush, et al.
Publicado: (2023)

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat
por: van Velsen, Evert F S, et al.
Publicado: (2023)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

Ultrasound-guided implantation of radioactive (125)I seed in radioiodine refractory differentiated thyroid carcinoma
por: Chen, Wei, et al.
Publicado: (2021)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Focal Bronchiectasis Causing Abnormal Pulmonary Radioiodine Uptake in a Patient with Well-Differentiated Papillary Thyroid Carcinoma
por: Gargya, Ash, et al.
Publicado: (2012)

Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
por: Samimi, Hilda, et al.
Publicado: (2022)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
por: Colombo, Carla, et al.
Publicado: (2020)

Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma
por: Kaewchur, Tawika, et al.
Publicado: (2021)

Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f3q285b0b0ng79od4p1133d1e1